Objective: To identify genetic variants that influence steady-state etonogestrel concentrations among contraceptive implant users.
Methods: We enrolled healthy, reproductive-age women in our pharmacogenomic study using etonogestrel implants for 12-36 months without concomitant use of hepatic enzyme inducers or inhibitors. We collected participant characteristics, measured serum etonogestrel concentrations, and genotyped each participant for 120 single nucleotide variants in 14 genes encoding proteins involved in steroid hormone (ie, estrogens, progestins) metabolism, regulation, or function. We performed generalized linear modeling to identify genetic variants associated with steady-state etonogestrel concentrations.
Results: We enrolled 350 women, who had a median serum etonogestrel concentration of 137.4 pg/mL (range 55.8-695.1). Our final generalized linear model contained three genetic variants associated with serum etonogestrel concentrations: NR1I2(PXR) rs2461817 (β=13.36, P=.005), PGR rs537681 (β=-29.77, P=.007), and CYP3A7*1C (β=-35.06, P=.025). Variant allele frequencies were 69.4%, 84.9%, and 5.1%, respectively. Our linear model also contained two nongenetic factors associated with etonogestrel concentrations: body mass index (BMI) (β=-3.08, P=7.0×10) and duration of implant use (β=-1.60, P=5.8×10); R for the model =0.17.
Conclusion: Only BMI and duration of implant use remained significantly associated with steady-state etonogestrel concentrations. Of the three novel genetic associations found, one variant associated with increased etonogestrel metabolism (CYP3A7*1C) causes adult expression of fetal CYP3A7 proteins and can consequently alter steroid hormone metabolism. Women with this variant may potentially have increased metabolism of all steroid hormones, as 27.8% (5/18) of CYP3A7*1C carriers had serum etonogestrel concentrations that fell below the threshold for consistent ovulatory suppression (less than 90 pg/mL). More pharmacogenomic investigations are needed to advance our understanding of how genetic variation can influence the effectiveness and safety of hormonal contraception, and lay the groundwork for personalized medicine approaches in women's health.
Clinical Trial Registration: ClinicalTrials.gov, NCT03092037.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448146 | PMC |
| http://dx.doi.org/10.1097/AOG.0000000000003189 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
D-peptide hydrogels as a long-acting multipurpose drug delivery platform for combined contraception and HIV prevention.
J Control Release
January 2025
School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast, Northern Ireland BT9 7BL, United Kingdom. Electronic address:
Article Synopsis
- New multipurpose prevention technologies for women prioritize reducing HIV risks and preventing unwanted pregnancies, promoting greater sexual health choices.
- A novel long-acting injectable platform combines the HIV drug MIV-150 and the contraceptive etonogestrel using a specially designed D-peptide that forms a drug-releasing hydrogel after injection.
- The technology shows promising biostability, low toxicity, and sustained delivery of both drugs in animal models for nearly 50 days, indicating its potential for effective long-term use.
Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women with HIV.
J Infect Dis
October 2024
Department of Pediatrics, University of California, Los Angeles, Los Angeles, California, USA.
Background: HIV-1 antiretroviral therapy (ART) alters hormonal contraceptive levels delivered via intravaginal ring (IVR) in a regimen specific manner. We explored the role of the IVR on vaginal microbial communities, vaginal short chain fatty acids (SCFAs), vaginal HIV shedding, and the effect of vaginal microbes on hormone concentrations in cisgender women with HIV (WWH).
Methods: Vaginal microbes were assessed by 16S RNA sequencing of weekly vaginal swabs, vaginal SCFA by mass spectrometry, HIV-1 shedding by nucleic acid amplification on vaginal aspirates, and bacterial vaginosis by Nugent scoring from 74 participants receiving an etonorgestrel/ethinyl estradiol (ENG/EE) intravaginal ring while on no ART (N=25), efavirenz-based ART (N=25), or atazanavir-based ART (N=24).
Comparison of etonogestrel bioanalytical assay results in plasma and serum within and across laboratories.
Contraception
February 2025
Antiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address:
Article Synopsis
- This study aimed to compare how different laboratories measure etonogestrel, a contraceptive hormone, focusing on accuracy and precision across six labs (five academic and one commercial).
- In tests with prepared serum and plasma samples, four labs achieved accurate results within ±15% of expected concentrations, while high precision was demonstrated, with minimal variation across results.
- However, while individual labs generally correlated well with a reference lab for serum samples, some showed biases resulting in consistently higher or lower readings, highlighting variability in etonogestrel measurement methods across different facilities.
Effect of progestin-based contraceptives on HIV-associated vaginal immune biomarkers and microbiome in adolescent girls.
PLoS One
July 2024
Department of Epidemiology, George Washington University, Washington, DC, United States of America.
Adolescent girls bear a disproportionate burden of both the HIV epidemic and unintended pregnancies; yet important questions remain unanswered regarding the effects of hormonal contraceptives on the vaginal immune microenvironment, which can impact HIV susceptibility in this group. Multiple studies report genital immune alterations associated with the progestin-based contraceptive Depot medroxyprogesterone acetate (DMPA) in adult women, but there is little available data in adolescents. The objective of this longitudinal cohort study was to evaluate the effects of short-term use of three progestin-based contraceptives, levonorgestrel intrauterine device (LNG-IUD), subdermal etonogestrel (ETNG), and injectable DMPA, on HIV-associated vaginal immune biomarkers and microbiome in adolescent girls.
View Article and Find Full Text PDFThe influence of lifestyle factors on serum etonogestrel concentrations among contraceptive implant users.
Contraception
December 2024
University Hospitals Cleveland Medical Center and Case Western Reserve University, Department of Obstetrics and Gynecology, Cleveland, OH, USA.
Objective: To evaluate how diet, exercise, and substance use influence serum etonogestrel concentrations among contraceptive implant users.
Study Design: We conducted a cross-sectional analysis of healthy, reproductive-age etonogestrel implant users. We assessed participants' current diet, exercise, and substance (alcohol, tobacco, marijuana) use habits while simultaneously measuring serum etonogestrel concentrations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!